RGNX - Regenxbio Inc
IEX Last Trade
12.25
0.250 2.041%
Share volume: 296,676
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.00
0.25
2.08%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-28 | 2023-05-03 | 2023-08-02 | 2023-11-08 | 2024-02-27 | 2024-05-08 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 883.793 M | 833.268 M | 747.830 M | 682.458 M | 633.786 M | 573.970 M | 629.215 M | 569.379 M | |
| Current Assets | 436.639 M | 415.976 M | 389.202 M | 378.809 M | 365.838 M | 334.971 M | 395.418 M | 346.683 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 21.672 M | 23.252 M | 38.524 M | 37.347 M | 35.908 M | 34.923 M | 40.887 M | 33.517 M | |
| Short Term Investments | 21.672 M | 23.252 M | 38.524 M | 37.347 M | 35.908 M | 34.923 M | 40.887 M | 33.517 M | |
| Total Receivables | 32.549 M | 28.082 M | 18.861 M | 21.380 M | 28.043 M | 24.790 M | 15.828 M | 22.809 M | |
| Current Cash | 382.418 M | 364.642 M | 331.817 M | 320.082 M | 301.887 M | 275.258 M | 338.703 M | 290.357 M | |
| Total Non-current Assets | 447.154 M | 417.292 M | 358.628 M | 303.649 M | 267.948 M | 238.999 M | 233.797 M | 222.696 M | |
| Property Plant Equipment | 140.906 M | 141.685 M | 141.573 M | 138.680 M | 135.534 M | 132.103 M | 127.662 M | 123.969 M | |
| Other Assets | 10.153 M | 7.901 M | 9.590 M | 4.976 M | 5.747 M | 5.508 M | 4.740 M | 3.410 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 883.793 M | 833.268 M | 747.830 M | 682.458 M | 633.786 M | 573.970 M | 629.215 M | 569.379 M | |
| Total liabilities | 319.969 M | 317.073 M | 282.691 M | 276.603 M | 270.686 M | 262.228 M | 238.549 M | 221.112 M | |
| Total current liabilities | 123.548 M | 130.434 M | 112.334 M | 117.893 M | 127.346 M | 130.272 M | 110.179 M | 98.273 M | |
| Accounts Payable | 25.210 M | 27.213 M | 23.283 M | 11.639 M | 21.859 M | 22.786 M | 31.356 M | 16.362 M | |
| Other liabilities | 111.748 M | 97.837 M | 83.365 M | 73.456 M | 59.282 M | 49.734 M | 48.187 M | 44.605 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 111.748 M | 97.837 M | 83.365 M | 73.456 M | 59.282 M | 49.734 M | 48.187 M | 44.605 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 563.824 M | 516.195 M | 465.139 M | 405.855 M | 363.100 M | 311.742 M | 390.666 M | 348.267 M | |
| Common stock | 43.251 M | 43.302 M | 43.451 M | 43.531 M | 43.945 M | 44.009 M | 45.733 M | 50.601 M | |
| Retained earnings | -381.618 M | -441.553 M | -508.229 M | -580.290 M | -642.158 M | -705.047 M | -768.377 M | -821.366 M |